Free Trial
→ Trump’s Sending THIS Crypto Higher on Purpose (From Crypto 101 Media) (Ad)

Brookline Capital Management Analyst Recommendations & Stock Picks

This page lists the most recent publicly-reported stock recommendations and ratings issued by analysts at Brookline Capital Management. These ratings and price targets were collected from public media reports and are believed to be accurate, but cannot be verified with 100% certainty. MarketBeat and its parent company are in no way affiliated with or endorsed by Brookline Capital Management.

MarketRank™ evaluates a company based on dividend strength, earnings, valuation, analysts forecasts, and more.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
Export to Excel
CompanyCurrent PriceRating DateActionBrokerageAnalystRatingPrice TargetImpact on PriceDetailsActions
Quince Therapeutics stock logo
QNCX
Quince Therapeutics
$1.78
+1.1%		12/18/2024Initiated byBrookline Capital ManagementAnalyst K. RajaBuy$9.00N/AView details for Brookline Capital Management rating of Quince Therapeutics (NASDAQ:QNCX) on 12/18/2024
CervoMed stock logo
CRVO
CervoMed
$2.23
12/10/2024Downgraded byBrookline Capital ManagementAnalyst T. BussianStrong-Buy -> HoldN/AView details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 12/10/2024
Y-mAbs Therapeutics stock logo
YMAB
Y-mAbs Therapeutics
$8.28
-3.4%		12/4/2024Upgraded byBrookline Capital ManagementAnalyst K. DolliverStrong-BuyN/AView details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/4/2024
Y-mAbs Therapeutics stock logo
YMAB
Y-mAbs Therapeutics
$8.28
-3.4%		12/5/2024Initiated byBrookline Capital Management-Buy$17.00N/AView details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/5/2024
Envoy Medical stock logo
COCH
Envoy Medical
$1.65
-10.3%		10/14/2024Initiated byBrookline Capital ManagementAnalyst T. BussianBuy$9.00LowView details for Brookline Capital Management rating of Envoy Medical (NASDAQ:COCH) on 10/14/2024
Verrica Pharmaceuticals stock logo
VRCA
Verrica Pharmaceuticals
$0.69
+2.6%		10/2/2024Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuy -> HoldHighView details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 10/2/2024
OS Therapies stock logo
OSTX
OS Therapies
$3.97
+1.5%		8/22/2024Upgraded byBrookline Capital ManagementAnalyst K. RajaStrong-BuyLowView details for Brookline Capital Management rating of OS Therapies (NYSE:OSTX) on 8/22/2024
MEI Pharma stock logo
MEIP
MEI Pharma
$2.50
+2.0%		7/22/2024Downgraded byBrookline Capital ManagementAnalyst L. CannStrong-Buy -> HoldLowView details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 7/22/2024
iBio stock logo
IBIO
iBio
$2.48
+2.5%		7/22/2024Initiated byBrookline Capital ManagementAnalyst K. DolliverBuy$3.60LowView details for Brookline Capital Management rating of iBio (NYSE:IBIO) on 7/22/2024
Unicycive Therapeutics stock logo
UNCY
Unicycive Therapeutics
$0.68
-4.2%		7/9/2024Upgraded byBrookline Capital ManagementAnalyst K. RajaStrong-BuyLowView details for Brookline Capital Management rating of Unicycive Therapeutics (NASDAQ:UNCY) on 7/9/2024
CervoMed stock logo
CRVO
CervoMed
$2.23
7/8/2024Initiated byBrookline Capital ManagementAnalyst T. BussianBuy$63.00LowView details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 7/8/2024
SAB Biotherapeutics stock logo
SABS
SAB Biotherapeutics
$4.65
+19.2%		6/7/2024Initiated byBrookline Capital Management-Buy$8.00LowView details for Brookline Capital Management rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/7/2024
Aileron Therapeutics stock logo
ALRN
Aileron Therapeutics
$1.75
-0.6%		5/30/2024Upgraded byBrookline Capital ManagementAnalyst K. DolliverStrong-BuyLowView details for Brookline Capital Management rating of Aileron Therapeutics (NASDAQ:ALRN) on 5/30/2024
Forte Biosciences stock logo
FBRX
Forte Biosciences
$19.34
+3.6%		5/30/2024Initiated byBrookline Capital Management-Buy$4.00LowView details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 5/30/2024
Daré Bioscience stock logo
DARE
Daré Bioscience
$2.71
-9.1%		5/15/2024Upgraded byBrookline Capital ManagementAnalyst K. DolliverHold -> Buy$36.00LowView details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 5/15/2024
Daré Bioscience stock logo
DARE
Daré Bioscience
$2.71
-9.1%		4/17/2024Downgraded byBrookline Capital ManagementAnalyst K. DolliverBuy -> HoldN/AView details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/17/2024
Immunic stock logo
IMUX
Immunic
$1.00
-3.8%		4/5/2024Reiterated byBrookline Capital ManagementAnalyst T. BussianBuy$10.00LowView details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
$0.22
3/4/2024Downgraded byBrookline Capital ManagementAnalyst K. DolliverBuy -> HoldLowView details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024
Annovis Bio stock logo
ANVS
Annovis Bio
$4.37
-0.7%		2/28/2024Downgraded byBrookline Capital ManagementAnalyst T. BussianBuy -> Hold$9.00LowView details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024
Outlook Therapeutics stock logo
OTLK
Outlook Therapeutics
$1.44
+3.6%		1/25/2024Upgraded byBrookline Capital ManagementAnalyst K. DolliverHold -> Buy$31.40LowView details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 1/25/2024
Lantheus stock logo
LNTH
Lantheus
$89.29
-2.9%		11/30/2023Initiated byBrookline Capital Management-Buy$100.00LowView details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023
Annovis Bio stock logo
ANVS
Annovis Bio
$4.37
-0.7%		11/10/2023Reiterated byBrookline Capital ManagementAnalyst T. BussianBuy$35.00LowView details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023
Genelux stock logo
GNLX
Genelux
$2.27
+3.7%		10/30/2023Upgraded byBrookline Capital ManagementAnalyst K. DolliverHold -> BuyLowView details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023
Procaps Group stock logo
PROC
Procaps Group
$2.51
+2.9%		9/6/2023Downgraded byBrookline Capital ManagementAnalyst K. DolliverBuy -> Hold$4.50LowView details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 9/6/2023
Outlook Therapeutics stock logo
OTLK
Outlook Therapeutics
$1.44
+3.6%		8/30/2023Downgraded byBrookline Capital ManagementAnalyst K. DolliverBuy -> HoldLowView details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/30/2023
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
$0.22
8/14/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLowView details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023
Daré Bioscience stock logo
DARE
Daré Bioscience
$2.71
-9.1%		2/14/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLowView details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 2/14/2023
electroCore stock logo
ECOR
electroCore
$15.27
+5.2%		1/12/2023Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/AView details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023
Imunon stock logo
IMNN
Imunon
$0.83
-2.8%		11/14/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLowView details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 11/14/2022
Vaxart stock logo
VXRT
Vaxart
$0.62
+2.7%		10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLowView details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022
Outlook Therapeutics stock logo
OTLK
Outlook Therapeutics
$1.44
+3.6%		10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLowView details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 10/3/2022
Monopar Therapeutics stock logo
MNPR
Monopar Therapeutics
$25.82
+8.5%		10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLowView details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022
Lisata Therapeutics stock logo
LSTA
Lisata Therapeutics
$2.71
+7.5%		10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLowView details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022
Imunon stock logo
IMNN
Imunon
$0.83
-2.8%		10/3/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLowView details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 10/3/2022
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
$15.48
+4.3%		8/10/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLowView details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
$0.22
6/30/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/AView details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022
Veru stock logo
VERU
Veru
$0.65
+3.3%		5/18/2022Target Raised byBrookline Capital ManagementAnalyst Kumaraguru RajaBuy -> Buy$29.00 -> $31.00MediumView details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022
Verrica Pharmaceuticals stock logo
VRCA
Verrica Pharmaceuticals
$0.69
+2.6%		3/10/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyMediumView details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022
Intellia Therapeutics stock logo
NTLA
Intellia Therapeutics
$12.18
+0.8%		3/7/2022Upgraded byBrookline Capital ManagementAnalyst L. CannHold -> Buy$91.00HighView details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022
CRISPR Therapeutics stock logo
CRSP
CRISPR Therapeutics
$40.72
+0.8%		2/14/2022Reiterated byBrookline Capital ManagementAnalyst Leah RushBuy$143.00HighView details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]
Intellia Therapeutics stock logo
NTLA
Intellia Therapeutics
$12.18
+0.8%		2/14/2022Reiterated byBrookline Capital ManagementAnalyst Leah RushBuyLowView details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022
Caribou Biosciences stock logo
CRBU
Caribou Biosciences
$1.80
-0.6%		2/14/2022Reiterated byBrookline Capital ManagementAnalyst L. CannBuyMediumView details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022
IceCure Medical stock logo
ICCM
IceCure Medical
$1.12
-2.6%		2/1/2022Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyLowView details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022
Daré Bioscience stock logo
DARE
Daré Bioscience
$2.71
-9.1%		1/19/2022Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHighView details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 1/19/2022
Procaps Group stock logo
PROC
Procaps Group
$2.51
+2.9%		12/14/2021Reiterated byBrookline Capital ManagementAnalyst Kemp DolliverBuy$13.00LowView details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 12/14/2021
Kymera Therapeutics stock logo
KYMR
Kymera Therapeutics
$40.66
+3.9%		10/13/2021Reiterated byBrookline Capital ManagementAnalyst Leah Rush CannBuy$80.00MediumView details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021
Forte Biosciences stock logo
FBRX
Forte Biosciences
$19.34
+3.6%		9/3/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaHoldLowView details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021
Veru stock logo
VERU
Veru
$0.65
+3.3%		8/27/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMediumView details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021
SCYNEXIS stock logo
SCYX
SCYNEXIS
$1.00
-1.0%		8/24/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLowView details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021
C4 Therapeutics stock logo
CCCC
C4 Therapeutics
$3.95
+2.6%		6/25/2021Reiterated byBrookline Capital ManagementAnalyst Leah Rush CannBuyHighView details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021
Antibe Therapeutics stock logo
ATBPF
Antibe Therapeutics
$0.22
6/3/2021Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyMediumView details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021
Monopar Therapeutics stock logo
MNPR
Monopar Therapeutics
$25.82
+8.5%		5/25/2021Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyMediumView details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021
Bioceres Crop Solutions stock logo
BIOX
Bioceres Crop Solutions
$6.19
+1.6%		5/7/2021Reiterated byBrookline Capital ManagementAnalyst K. DolliverBuyN/AView details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021
Moderna stock logo
MRNA
Moderna
$39.39
-0.4%		2/26/2021Target Raised byBrookline Capital Management-Buy$180.00 -> $205.00LowView details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021
X4 Pharmaceuticals stock logo
XFOR
X4 Pharmaceuticals
$0.61
+0.4%		12/17/2020Initiated byBrookline Capital ManagementAnalyst L. CannBuy$21.00HighView details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020
Veru stock logo
VERU
Veru
$0.65
+3.3%		12/14/2020Target Raised byBrookline Capital ManagementAnalyst K. Raja$13.00 -> $17.00HighView details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020
electroCore stock logo
ECOR
electroCore
$15.27
+5.2%		10/23/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuy$75.00LowView details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020
Aspira Women's Health stock logo
AWH
Aspira Women's Health
$0.77
+0.7%		10/14/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyHighView details for Brookline Capital Management rating of Aspira Women’s Health (NASDAQ:AWH) on 10/14/2020
MEI Pharma stock logo
MEIP
MEI Pharma
$2.50
+2.0%		10/12/2020Reiterated byBrookline Capital ManagementAnalyst L. CannBuyMediumView details for Brookline Capital Management rating of MEI Pharma (NASDAQ:MEIP) on 10/12/2020
Forte Biosciences stock logo
FBRX
Forte Biosciences
$19.34
+3.6%		8/28/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy$90.00LowView details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020
Kura Oncology stock logo
KURA
Kura Oncology
$9.01
+0.4%		8/16/2020Reiterated byBrookline Capital ManagementAnalyst L. CannBuyLowView details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020
Veru stock logo
VERU
Veru
$0.65
+3.3%		8/14/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLowView details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
$15.48
+4.3%		8/11/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLowView details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020
Moderna stock logo
MRNA
Moderna
$39.39
-0.4%		7/13/2020Reiterated byBrookline Capital ManagementAnalyst L. CannBuy$95.00HighView details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020
Assertio stock logo
ASRT
Assertio
$0.89
+5.1%		6/3/2020Initiated byBrookline Capital Management-Buy$3.50LowView details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020
Outlook Therapeutics stock logo
OTLK
Outlook Therapeutics
$1.44
+3.6%		5/5/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuyHighView details for Brookline Capital Management rating of Outlook Therapeutics (NASDAQ:OTLK) on 5/5/2020
Daré Bioscience stock logo
DARE
Daré Bioscience
$2.71
-9.1%		4/28/2020Initiated byBrookline Capital ManagementAnalyst S. YanchusBuy$90.00HighView details for Brookline Capital Management rating of Daré Bioscience (NASDAQ:DARE) on 4/28/2020
ClearPoint Neuro stock logo
CLPT
ClearPoint Neuro
$15.55
+6.1%		3/11/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyHighView details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020
Armata Pharmaceuticals stock logo
ARMP
Armata Pharmaceuticals
$1.95
-1.5%		3/13/2020Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHighView details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020
ClearPoint Neuro stock logo
CLPT
ClearPoint Neuro
$15.55
+6.1%		3/12/2020Initiated byBrookline Capital Management-Buy$15.00N/AView details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020
Monopar Therapeutics stock logo
MNPR
Monopar Therapeutics
$25.82
+8.5%		2/19/2020Initiated byBrookline Capital ManagementAnalyst K. RajaBuy$210.00HighView details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020
Bioceres Crop Solutions stock logo
BIOX
Bioceres Crop Solutions
$6.19
+1.6%		2/4/2020Reiterated byBrookline Capital ManagementAnalyst S. YanchusBuyN/AView details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020
Medicenna Therapeutics stock logo
MDNA
Medicenna Therapeutics
C$1.71
+1.8%		11/19/2019Reiterated byBrookline Capital Management-BuyC$4.00N/AView details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019
SCYNEXIS stock logo
SCYX
SCYNEXIS
$1.00
-1.0%		8/19/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHighView details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019
Vaxart stock logo
VXRT
Vaxart
$0.62
+2.7%		8/15/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy$6.00LowView details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019
Veru stock logo
VERU
Veru
$0.65
+3.3%		7/29/2019Initiated byBrookline Capital ManagementAnalyst K. RajaBuy$12.00HighView details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
$15.48
+4.3%		7/24/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHighView details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019
SCYNEXIS stock logo
SCYX
SCYNEXIS
$1.00
-1.0%		1/4/2019Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyHighView details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019
Arcturus Therapeutics stock logo
ARCT
Arcturus Therapeutics
$15.48
+4.3%		9/27/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLowView details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018
Tonix Pharmaceuticals stock logo
TNXP
Tonix Pharmaceuticals
$0.61
+7.3%		7/27/2018Downgraded byBrookline Capital ManagementAnalyst K. RajaBuy -> HoldLowView details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018
Tonix Pharmaceuticals stock logo
TNXP
Tonix Pharmaceuticals
$0.61
+7.3%		5/1/2018Reiterated byBrookline Capital ManagementAnalyst K. RajaBuyLowView details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018

MarketBeat Community Rating for Brookline Capital Management

Community Ranking:  2.7 out of 5 (
2.7 of 5 stars)
Outperform Votes:  33,832 (Vote Outperform)
Underperform Votes:  28,735 (Vote Underperform)
Total Votes:  62,567
MarketBeat's community ratings are surveys of what our community members think about Brookline Capital Management and other research firms. Vote "Outperform" if you believe Brookline Capital Management's recommendations will outperform the S&P 500 over the long term. Vote "Underperform" if you believe Brookline Capital Management's recommendations will underperform the S&P 500 over the long term. You may vote once every thirty days.
Today's Ratings
Top Rated Stocks
More Ratings Tools